Emmett Cunningham - 14 Jun 2023 Form 4 Insider Report for Galera Therapeutics, Inc. (GRTX)

Role
Director
Signature
/s/ Emmett Cunningham
Issuer symbol
GRTX
Transactions as of
14 Jun 2023
Net transactions value
$0
Form type
4
Filing time
16 Jun 2023, 16:15:10 UTC
Previous filing
16 Jun 2022
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction GRTX Stock Option (Right to Buy) Award $0 +48,000 $0.000000* 0 14 Jun 2023 Common Stock 48,000 $3.27 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This option shall vest and become exercisable on the earlier of June 14, 2024 or the day immediately prior to the date of the Issuer's next annual meeting of stockholders occurring after the date of grant, in either case subject to the Reporting Person continuing in service on the Board as a Non-Employee Director through such vesting date.
F2 The Reporting Person disclaims beneficial ownership of these securities and the inclusion of the securities in this report shall not be deemed an admission of beneficial ownership for purposes of Section 16 or any other purpose. The Reporting Person is an employee of Blackstone Inc. or one of its affiliates ("Blackstone"). Pursuant to arrangements between the Reporting Person and Blackstone, the Reporting Person is required to transfer to Blackstone any and all compensation received in connection with his directorship for any company Blackstone invests in or advises.

Remarks:

Dr. Cunningham, an employee of an affiliate of Blackstone, is a member of the board of directors of the issuer. Dr. Cunningham disclaims beneficial ownership of any securities of the issuer that may be deemed to be beneficially owned by affiliates of Blackstone.